SUWANEE, GA--(Marketwired - Sep 10, 2013) - Digirad Corporation (
Digirad President and CEO Matthew G. Molchan said, "This agreement is exactly in line with our continued strategy to focus on driving income, cash flow and growth from our businesses at Digirad. As we have stated previously, we continue to believe our nuclear imaging cameras, with their solid-state design and technology, are well suited to meet the needs of the health-care industry, both domestically and internationally. With this new agreement, our camera production will become more cost effective, nimble and flexible to meet the demands of our customers and the market. Further, with this move to outsource manufacturing of our cameras, as well as our recent announcement to partner with Dilon Diagnostics to distribute our cameras internationally, we believe we are well-positioned to take advantage of these domestic and international opportunities in a very cost effective manner."
About Digirad Corporation
Digirad is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers, and also sells medical diagnostic imaging systems for nuclear cardiology and general nuclear medicine applications. For more information, please visit www.digirad.com. Digirad® and Cardius® are registered trademarks of Digirad Corporation.
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding the Company's ability to deliver value to customers, the Company's ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with changes in business conditions, technology, customers' business conditions, reimbursement, radiopharmaceutical shortages, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, analysis of potential impairment and restructuring charges, the conclusion of our audit and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.